Syndrome News and Research

RSS

Study reports robust immunity to SARS-CoV-2 including Omicron BA.1 for all three primary vaccines

In a recent study posted to the medRxiv* pre-print server, researchers in the United Kingdom investigated the effect of two Pfizer/BioNTech BNT162b2 vaccine doses or Oxford/AstraZeneca AZ1222 coronavirus disease 2019 (COVID-19) vaccination and a subsequent BNT162b2 booster dose in a cohort of healthcare workers (HCWs) over six to nine months.

10 Jun 2022

A comparison of SARS-CoV-2 and influenza cytokine storms

In a recent study published in the Journal of Interferon & Cytokine Research, researchers compared the cytokine storms of pandemic influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

9 Jun 2022

Aspirin changes the way colorectal cancer cells evolve over time, study reveals

Cancer starts when cells start dividing uncontrollably. Scientists have known that taking aspirin can help protect against the development of colorectal cancer – cancer afflicting the colon or rectum – but the exact reason aspirin has this effect has been mostly a mystery.

9 Jun 2022

New electrical test to screen individuals at risk of sudden cardiac arrest

New research from the Victor Chang Cardiac Research Institute will allow families around the world to discover if they are carrying genetic mutations that cause sudden cardiac arrest – a condition that kills nine out of 10 victims.

9 Jun 2022

Comparison of the strictness of the Shanghai lockdown policy with that of other countries

Researchers investigated whether strict lockdowns could effectively reduce the SARS-CoV-2 Omicron variant transmission in Shanghai.

9 Jun 2022

The presence of residual SARS-CoV-2 antigens in post-convalescent tissues

Researchers investigated the residual SARS-CoV-2 antigen found in long COVID-19 patients.

9 Jun 2022

The effectiveness of non-pharmacological treatments for post-viral syndromes and long COVID

A recent systematic review investigated the effectiveness of non-pharmacologic interventions for post-viral syndromes, including the post-COVID-19 syndrome.

9 Jun 2022

Insights on the T cell epitope landscape for the five main SARS-CoV-2 variants of concern

Researchers generated an AI resource to characterize the T cell epitope landscape for SARS-CoV-2 variants of concern.

9 Jun 2022

Cognitive impairment and function in SARS-CoV-2 positive patients

Researchers assessed the association between post-acute COVID-19 cognitive impairment and kynurenine pathway activation.

9 Jun 2022

SARS-CoV-2 is a generalist virus, infecting and evolving in numerous mammals and humans

In a recent article published in the bioRxiv* preprint server, researchers illustrated zooanthroponotic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission and viral mutations specific to hosts.

8 Jun 2022

Research suggests two protein coding genes can predict severe COVID-19

In a recent study posted to the medRxiv* pre-print server, researchers demonstrated that two genes, GTPase, IMAP Family Member 7 (GIMAP7), and sphingosine-1-phosphate receptor 2 (S1PR2), have the potential to predict severe coronavirus disease 2019 (COVID-19) with ~90% accuracy.

8 Jun 2022

SARS-CoV-2 ORF8 protein binds to dendritic cells and induces a hyper-inflammatory cytokine storm

In a recent study posted to the bioRxiv* pre-print server, researchers examined how the interaction of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) open reading frame 8 (ORF8) protein with host dendritic cells (DCs) induced cytokine storm.

8 Jun 2022

Study on the underlying biology of long COVID

In a recent article published in the Science Translational Medicine journal, researchers analyzed prolonged and unique implications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans and hamsters following recovery.

8 Jun 2022

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

In a recent study published in the Lancet, researchers evaluated the safety and efficacy of tixagevimab–cilgavimab, a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) combination in patients with mild to moderate coronavirus disease 2019 (COVID-19).

8 Jun 2022

Syndrome News and Research

Study reports robust immunity to SARS-CoV-2 including Omicron BA.1 for all three primary vaccines

A comparison of SARS-CoV-2 and influenza cytokine storms

Aspirin changes the way colorectal cancer cells evolve over time, study reveals

New electrical test to screen individuals at risk of sudden cardiac arrest

Comparison of the strictness of the Shanghai lockdown policy with that of other countries

The presence of residual SARS-CoV-2 antigens in post-convalescent tissues

The effectiveness of non-pharmacological treatments for post-viral syndromes and long COVID

Insights on the T cell epitope landscape for the five main SARS-CoV-2 variants of concern

Cognitive impairment and function in SARS-CoV-2 positive patients

SARS-CoV-2 is a generalist virus, infecting and evolving in numerous mammals and humans

Research suggests two protein coding genes can predict severe COVID-19

SARS-CoV-2 ORF8 protein binds to dendritic cells and induces a hyper-inflammatory cytokine storm

Study on the underlying biology of long COVID

Safety and efficacy of tixagevimab–cilgavimab in preventing severe COVID

Ventilation key to reducing COVID-19 spread in schools

Electronic nose detects SARS-CoV-2 from breath

Women with PCOS more likely to be diagnosed with additional medical conditions, study shows

Study demonstrates mental health changes in the adult European population during the COVID-19 pandemic

The association between vitamin D status and infections, hospitalization, and mortality due to COVID-19

The cumulative risk of myocarditis/myopericarditis among global mRNA-1273 recipients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News